Clinical trials
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma clinical trials
Below are recruiting recurrent/metastatic head and neck squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 40 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07667400RecruitingPhase 1/Phase 2
Docetaxel plus SX-682 for advanced head and neck or prostate cancer
This trial studies a combination of the chemotherapy drug docetaxel and an investigational drug called SX-682 for people with certain advanced head and neck cancers or prostate cancer. The goal is to see if the combination is safe and effective.
Bethesda, MarylandAges 18–120 - NCT04681469RecruitingPhase 2
Niraparib plus immunotherapy for HPV-negative head and neck cancer
This Phase 2 study tests a cancer “induction then maintenance” plan using a PARP inhibitor (niraparib) along with immunotherapy (TSR-042) in people with HPV-negative head and neck squamous cell cancer. If it works, it may improve control of the cancer after surgery by boosting the immune system and targeting cancer cells’ DNA repair.
BresciaAges 18 years+ - NCT07791745RecruitingPhase 2/Phase 3
Comparing treatments for advanced head and neck cancer
This trial tests a new combination of treatments for head and neck cancer that has returned or spread and can't be cured with local therapy. It compares a standard chemotherapy with or without an additional drug to see which is more effective and safe.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06007729RecruitingPhase 2
A study of HS-20093 for head and neck cancer and other solid tumors
This trial tests a new drug, HS-20093, in people with head and neck squamous cell carcinoma or other solid tumors that have worsened after standard treatments. The goal is to see if the drug can help shrink or slow the growth of these cancers.
Hefei, AnhuiAges 18 years+ - NCT05286619RecruitingPhase 2
Pembrolizumab with chemotherapy for recurrent head and neck cancer
This trial studies whether pembrolizumab plus chemotherapy (platinum and gemcitabine) can control recurrent or metastatic head and neck squamous cell carcinoma that can’t be cured with local treatments. It may help shrink tumors and slow disease growth in people who haven’t had cancer medicines for this stage before.
Kuala LumpurAges 18 years+ - NCT07659678RecruitingPhase 2
Pet scan for head and neck cancer
This study tests a special PET/CT scan that may help doctors see the cancer more clearly in people with head and neck cancer, either at diagnosis or if it comes back.
St Louis, MissouriAges 18 years+ - NCT07662746RecruitingPhase 2
Paclitaxel micelles for advanced head and neck cancer
This trial tests a new form of chemotherapy called paclitaxel polymeric micelles for people with head and neck cancer that has come back or spread. It is for patients who have already tried one line of treatment and may benefit from a different option.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07584499RecruitingPhase 1
New drug test for children with EGFR-positive solid tumors
This study tests a new cancer drug called Becotatug Vedotin in children ages 2–18 with certain types of solid tumors (cancers that form in organs or tissues) that have an EGFR protein. The drug is designed to find tumors with this protein and attack cancer cells while sparing healthy ones.
Guangzhou, GuangdongAges 2–18 - NCT07512921Recruiting
Gene Expression Study for HPV-Negative Head and Neck Cancer
This study compares gene patterns in tumor tissue and blood samples from patients with HPV-negative head and neck cancer. Understanding these patterns may help doctors better understand the disease and develop better treatments.
MilanAges 18 years+ - NCT07485296RecruitingPhase 2
Postbiotics with pembrolizumab for advanced head and neck cancer
This trial tests whether adding postbiotics (beneficial bacteria byproducts) to the standard immunotherapy drug pembrolizumab can improve your immune system's response against advanced or metastatic head and neck squamous cell carcinoma.
Rozzano, MilanoAges 18 years+ - NCT07423078RecruitingPhase 2
Larynx preservation trial for advanced throat cancer
This trial tests a new approach to treat throat cancer while trying to preserve your larynx (voice box). It combines chemotherapy drugs and an immunotherapy drug before surgery or radiation. The goal is to see if this can help you avoid needing to have your larynx removed.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07408063RecruitingPhase 2
Study of new drug for advanced head and neck cancer
This trial tests a new drug (GSK5764227) for head and neck cancer that has spread or come back. It looks at your tumor's biomarkers to understand why some people respond to treatment. You may need to have had certain prior treatments depending on which group you join.
Toronto, OntarioAges 18 years+ - NCT06876844RecruitingPhase 2
Surufatinib plus Envolizumab for advanced head and neck cancer
This study tests a new combination of two drugs (Surufatinib and Envolizumab) as a second treatment option for people with head and neck cancer that has returned or spread. It's for patients whose first treatment (usually chemo or immunotherapy) stopped working within 6 months.
ShanghaiAges 18–75 - NCT06869473RecruitingPhase 2
Cetuximab, chemo, and avelumab for head and neck cancer
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
Cagliari, CAGLIARIAges 18 years+ - NCT07276399RecruitingPhase 3
Study of amivantamab plus standard care for head and neck cancer
This trial tests whether adding the drug amivantamab to usual treatments helps people with advanced head and neck cancer that has come back or spread. It compares the combination to standard care alone.
Chandler, ArizonaAges 18 years+ - NCT07264075RecruitingPhase 3
Ivonescimab with or without ligufalimab vs pembrolizumab for head and neck cancer
This trial tests a new immunotherapy combination (ivonescimab alone or with ligufalimab) against the standard immunotherapy pembrolizumab (Keytruda) for people with head and neck cancer that has come back or spread. It may be an option if you have not had any prior immunotherapy and your tumor is PD-L1 positive.
Le HavreAges 18–80 - NCT06905145Recruiting
Molecular testing for advanced head and neck cancer
This trial is for people with head and neck cancer that has not spread to distant parts of the body. It is a non-treatment study that will look at the molecular features of your tumor from a biopsy sample to help guide future treatment decisions.
NaplesAges 18 years+ - NCT07088211RecruitingPhase 2
New drug combo for first-line head and neck cancer
This trial tests a new drug combination (sacituzumab tirumotecan and toripalimab) as a first treatment for people with advanced head and neck squamous cell carcinoma that cannot be removed with surgery. The goal is to see if this treatment shrinks tumors and improves outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07090317RecruitingPhase 2
Testing Two Immunotherapy Drugs for Advanced Head and Neck Cancer
This trial tests two new immunotherapy drugs, iparomlimab and tuvonralimab, for people with head and neck squamous cell cancer that has spread or come back after at least 2 prior treatments. The goal is to see if this combination can shrink or slow the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07059221RecruitingPhase 1/Phase 2
New drug combo for advanced head and neck cancer
This trial tests a new combination of drugs (SHR-A2102 and Adebrelimab) with or without other anti-cancer therapies for head and neck cancer that has come back or spread. It aims to see if these treatments can shrink tumors or slow the disease.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07063212RecruitingPhase 2
Sacituzumab govitecan plus cetuximab for head and neck cancer
This trial tests a combination of two drugs—sacituzumab govitecan and cetuximab—for people with advanced head and neck cancer that has gotten worse after immunotherapy. The goal is to see if this new treatment can shrink or slow the cancer.
Basking Ridge, New JerseyAges 18 years+ - NCT06494995RecruitingPhase 2
AK104 and low-dose radiation for advanced head and neck cancer
This trial tests a new immunotherapy drug called AK104 (cadonilimab) combined with low-dose radiation for people with head and neck or nasopharyngeal cancer that has come back or spread and no longer responds to first treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06935188RecruitingPhase 2
Dalpiciclib plus cetuximab for certain head and neck cancers
This trial tests a new combination of two drugs (dalpiciclib and cetuximab) versus cetuximab alone for people with head and neck cancer that is HPV-negative, has not responded to prior immunotherapy, and is not curable with surgery. The goal is to see if the combination works better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06912087RecruitingPhase 1
Finding the right dose of a new combo for head and neck cancer
This trial tests a new three-drug combination for advanced head and neck cancer that cannot be cured by local treatments. It aims to find the best dose of a targeted therapy called Zanzalintinib when given with two standard immunotherapy and targeted drugs.
Chicago, IllinoisAges 18 years+
Hear when a new Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent/metastatic head and neck squamous cell carcinoma?
- Yes. Clin2 currently lists 40 recruiting recurrent/metastatic head and neck squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent/metastatic head and neck squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent/metastatic head and neck squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Head and Neck Squamous Cell Carcinoma
- Metastatic Head and Neck Squamous Cell Carcinoma
- Locally Recurrent Head and Neck Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- Head and Neck Cancer Squamous Cell Carcinoma
- Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
- Resectable Head and Neck Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.